Using expanded criteria for clinical trial inclusion could lead to nearly twice as many patients with advanced non-small-cell lung cancer being eligible for participation compared with traditional criteria, participants at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, heard.
The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.
Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.
Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.
Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.
Preliminary findings for a first-in-human study of JNJ-372 – a bispecific IgG antibody targeting both the EGFR and cMET receptors – have been reported at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Early results suggest that a novel antibody–drug conjugate directed against HER3 has antitumor activity and manageable safety in patients with EGFR-mutated metastatic non-small-cell lung cancer and acquired resistance to EGFR–tyrosine kinase inhibitors.
Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.
Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.
Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.
The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.
The response to treatment with immune checkpoint inhibitors varies according to EGFR mutant subtype in patients with non-small-cell lung cancer, US researchers report.
The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.
Patients with stage IV non-small-cell lung cancer and no more than three metastases derive an overall survival benefit from aggressive local consolidative therapy, suggest trial results.
Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.
Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.
A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.
US researchers have replicated previously described associations between patient and tumor characteristics and clinical outcomes using routinely collected clinical and genomic data for patients with non-small-cell lung cancer.
Previously untreated Asian patients with advanced ALK translocation-positive non-small-cell lung cancer derive a significant progression-free survival benefit from alectinib over crizotinib, indicate phase III trial results.